You may love weed, alcohol, and tobacco, but would you also like to invest in those things? AdvisorShares thinks you will. The actively managed exchange-traded funds company recently launched AdvisorShares VICE ETF, the only ETF solely concentrating on companies associated with alcohol, cannabis, and tobacco. Dan Ahrens is a Managing Director and Portfolio Manager at AdvisorShares, and he joins Cheddar to explain why investing in the VICE ETF is a good idea. Ahrens explains that those three industries tend to be stable despite the general market volatility. Ahrens is also bullish on the future of cannabis. He believes the legalization and federal recognition of the substance will only expand. As for alcohol, there has also been growth in that field. The alcohol industry had supplier revenue increase by 4.5% to $25.2 billion last year. Ahrens anticipates the field to continue improving.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More